Thirty patients with heart failure and New York Heart Association NYHA functional class II or III who were already receiving optimal heart failure treatment consisting of angiotensinogen-converting enzyme inhibitors or angiotensin receptor blockers, carvedilol, spironolactone, digitalis and furosemide were included in the study.
Se incluyeron en el estudio treinta pacientes con IC y clase funcional NYHA New York Heart Association II o III, recibiendo tratamiento optimizado para IC que incluía IECA y bloqueadores del receptor de la angiotensina, carvedilol, spironolactone, digital y furosemida.
Trinta pacientes com IC e classe funcional NYHA New York Heart Association II ou III, recebendo tratamento otimizado para IC que incluía IECA e bloqueadores do receptor da angiotensina, carvedilol, spironolactone, digital e furosemida foram incluídos no estudo.